News headlines about Inotek Pharmaceuticals Corp (NASDAQ:ITEK) have been trending negative this week, according to Alpha One. Alpha One, a unit of Accern, identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Alpha One ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Inotek Pharmaceuticals Corp earned a coverage optimism score of -0.36 on Alpha One’s scale. Alpha One also gave headlines about the biotechnology company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have effected AlphaOne’s analysis:
Shares of Inotek Pharmaceuticals Corp (NASDAQ:ITEK) opened at 1.65 on Friday. Inotek Pharmaceuticals Corp has a 1-year low of $1.50 and a 1-year high of $9.90. The stock’s 50 day moving average is $1.93 and its 200 day moving average is $3.51. The company’s market capitalization is $44.53 million.
Inotek Pharmaceuticals Corp (NASDAQ:ITEK) last posted its earnings results on Wednesday, May 10th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.39) by $0.01. On average, equities research analysts anticipate that Inotek Pharmaceuticals Corp will post ($1.70) EPS for the current fiscal year.
A number of research firms recently weighed in on ITEK. Canaccord Genuity set a $3.00 target price on shares of Inotek Pharmaceuticals Corp and gave the company a “buy” rating in a research note on Thursday, March 16th. Zacks Investment Research raised shares of Inotek Pharmaceuticals Corp from a “sell” rating to a “hold” rating in a research note on Tuesday, January 17th. Finally, HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Inotek Pharmaceuticals Corp in a research note on Friday, March 17th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Inotek Pharmaceuticals Corp currently has an average rating of “Buy” and a consensus target price of $5.75.
Inotek Pharmaceuticals Corp Company Profile
Inotek Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism.